Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

Per Soelberg Sorensen; Jan Lycke; Juha-Pekka Erälinna; Astrid Edland; Xingchen Wu; Jette Lautrup Frederiksen; Annette Oturai; Clas Malmeström; Egon Stenager; Finn Sellebjerg; Helle Bach Sondergaard; SIMCOMBIN study investigators

doi:10.1016/S1474-4422(11)70144-2

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

Per Soelberg Sorensen, Jan Lycke, Juha-Pekka Erälinna, Astrid Edland, Xingchen Wu, Jette Lautrup Frederiksen, Annette Oturai, Clas Malmeström, Egon Stenager, Finn Sellebjerg, Helle Bach Sondergaard, SIMCOMBIN study investigators

100 Citations (Scopus)

Abstract

Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy.

Original language	English
Journal	Lancet neurology
Volume	10
Issue number	8
Pages (from-to)	691-701
Number of pages	11
ISSN	1474-4422
DOIs	https://doi.org/10.1016/S1474-4422(11)70144-2
Publication status	Published - 2011

Keywords

Adolescent
Adult
Double-Blind Method
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Interferon-beta
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
Simvastatin
Young Adult

Access to Document

10.1016/S1474-4422(11)70144-2

Cite this

Sorensen, P. S., Lycke, J., Erälinna, J.-P., Edland, A., Wu, X., Frederiksen, J. L., Oturai, A., Malmeström, C., Stenager, E., Sellebjerg, F., Sondergaard, H. B., & SIMCOMBIN study investigators (2011). Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet neurology, 10(8), 691-701. https://doi.org/10.1016/S1474-4422(11)70144-2

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. / Sorensen, Per Soelberg; Lycke, Jan; Erälinna, Juha-Pekka et al.
In: Lancet neurology, Vol. 10, No. 8, 2011, p. 691-701.

Research output: Contribution to journal › Journal article › Research › peer-review

Sorensen, PS, Lycke, J, Erälinna, J-P, Edland, A, Wu, X, Frederiksen, JL, Oturai, A, Malmeström, C, Stenager, E, Sellebjerg, F , Sondergaard, HB & SIMCOMBIN study investigators 2011, 'Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial', Lancet neurology, vol. 10, no. 8, pp. 691-701. https://doi.org/10.1016/S1474-4422(11)70144-2

@article{88774822097245b4a0c2eb0568359ce0,

title = "Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial",

abstract = "Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy.",

keywords = "Adolescent, Adult, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Interferon-beta, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, Simvastatin, Young Adult",

author = "Sorensen, {Per Soelberg} and Jan Lycke and Juha-Pekka Er{\"a}linna and Astrid Edland and Xingchen Wu and Frederiksen, {Jette Lautrup} and Annette Oturai and Clas Malmestr{\"o}m and Egon Stenager and Finn Sellebjerg and Sondergaard, {Helle Bach} and {SIMCOMBIN study investigators}",

year = "2011",

doi = "10.1016/S1474-4422(11)70144-2",

language = "English",

volume = "10",

pages = "691--701",

journal = "Lancet neurology",

issn = "1474-4422",

publisher = "The/Lancet Publishing Group",

number = "8",

}

TY - JOUR

T1 - Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

AU - Sorensen, Per Soelberg

AU - Lycke, Jan

AU - Erälinna, Juha-Pekka

AU - Edland, Astrid

AU - Wu, Xingchen

AU - Frederiksen, Jette Lautrup

AU - Oturai, Annette

AU - Malmeström, Clas

AU - Stenager, Egon

AU - Sellebjerg, Finn

AU - Sondergaard, Helle Bach

AU - SIMCOMBIN study investigators

PY - 2011

Y1 - 2011

N2 - Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy.

AB - Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy.

KW - Adolescent

KW - Adult

KW - Double-Blind Method

KW - Drug Therapy, Combination

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Interferon-beta

KW - Male

KW - Middle Aged

KW - Multiple Sclerosis, Relapsing-Remitting

KW - Simvastatin

KW - Young Adult

U2 - 10.1016/S1474-4422(11)70144-2

DO - 10.1016/S1474-4422(11)70144-2

M3 - Journal article

C2 - 21742556

SN - 1474-4422

VL - 10

SP - 691

EP - 701

JO - Lancet neurology

JF - Lancet neurology

IS - 8

ER -

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this